Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection.

Autor:	Lattanzio N; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Acosta-Diaz C; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Villasmil RJ; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Kirkland Z; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Bass C; Internal Medicine, Sarasota Memorial Hospital, Sarasota, USA., Yenari S; Medicine, Sarasota Memorial Hospital, Sarasota, USA., Conte J; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Dawkins K; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Fonseca T; Clinical Research, Sarasota Memorial Hospital, Sarasota, USA., Grimes C; Internal Medicine, Sarasota Memorial Hospital, Sarasota, USA., Stewart A; Clinical Database Administration, Sarasota Memorial Hospital, Sarasota, USA., Geary ME; Quality Improvement, Sarasota Memorial Hospital, Sarasota, USA., Vore H; Pathology, Sarasota Memorial Hospital, Sarasota, USA., Hamad K; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Wiese-Rometsch W; Internal Medicine, Sarasota Memorial Hospital, Florida State University College of Medicine, Sarasota, USA., Fiorica J; Oncology, Sarasota Memorial Hospital, Sarasota, USA., Gordillo M; Infectious Disease, Sarasota Memorial Hospital, Sarasota, USA., Mercado R; Infectious Disease, Sarasota Memorial Hospital, Sarasota, USA., Voelker K; Pulmonology and Critical Care, Sarasota Memorial Hospital, Sarasota, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2021 Jul 30; Vol. 13 (7), pp. e16746. Date of Electronic Publication: 2021 Jul 30 (Print Publication: 2021).
DOI:	10.7759/cureus.16746
Abstrakt:	On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2021, Lattanzio et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu